Aims Aim was to assess the feasibility of serum markers to identify individuals at risk for gastro-oesophageal adenocarcinoma to reduce the number of individuals requiring invasive assessment by endoscopy.
Methods Blood samples from 56 patients with Barrett’s oesophagus and 202 non-Barrett controls who previously took part in a trial assessing the accuracy of the Cytosponge for Barrett’s oesophagus were assessed for serum pepsinogen (PG) 1 and 2, gastrin-17, trefoil factor 3 (TFF3) and Helicobacter pylori infection.
Results PG1 was pathological (<50 ng/mL) in 26 patients (10.1%), none of whom had Barrett’s oesophagus (p<0.001). Smoking and drinking had no influence on these results. Pathological PG1 was associated with stomach pain (p=0.029), disruption of sleep (p=0.027) and disruption of diet by symptoms (p=0.019). Serum TFF3 was not associated with any clinical parameter.
Conclusions Assessment of serum PG1 could be combined with a test for Barrett’s oesophagus to identify additional patients requiring endoscopy.
- barrett’s oesophagus
- gastric atrophy
- gastric cancer
This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
Statistics from Altmetric.com
Handling editor Tahir S Pillay.
Contributors JB and AM designed and coordinated the study. YX did the laboratory and data analysis at the Cambridge site. AL coordinated and supervised the laboratory analysis at the Magdeburg site. PM and RCF supervised the project and gave valuable input for data analysis and interpretation. JB drafted the manuscript which was reviewed by the other authors.
Funding RCF receives core funding form the Medical Research Council and infrastructure support from the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (BRC).
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval The study was approved by the local ethics committee (Rec. No. 10.H0308.71).
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.